$CELU

Celularity Inc (CELU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001752828 0001752828 2026-08-05 2026-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Celularity Inc (CELU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 LOAN agreement This Loan Agreement, dated as of June 29, 2026 (“ Agreement ”), is among Celularity Inc., a Delaware corporation (the “ Borrower ”), and Philip & Daniele Barach Family Trust (the “ Lender ” and, together with the Borrower,

Celularity Inc (CELU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001752828 0001752828 2026-06-19 2026-06-19 0001752828 CELU:ClassCommonStock0.0001ParValuePerShareMember 2026-06-19 2026-06-19 0001752828 CELU:WarrantsEachExercisableForOnetenthOfOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2026-06-19 2026-06-19 iso4217:US

This Simply Wall St analysis provides a detailed stock report for Celularity (Nasdaq:CELU), a regenerative and cellular medicines company, as of May 2026. The report covers valuation, future growth, past performance, financial health, dividend, management, and ownership, indicating a small market cap and negative shareholder equity. It also highlights recent news including funding, delayed filings, earnings reports, and clinical trial updates for its various product candidates.

This article highlights several stocks to watch on Friday after hours, including Cantaloupe, Inc. (CTLP), CELU, and ULH. It notes that the stock market closed modestly higher on Friday, starting May on an optimistic note due to retreating oil prices and strong corporate earnings. The S&P 500 rose by 0.3%.

Nexgel Inc. and Celularity have executed Amendment No. 1 to their license agreement on April 17, 2026. This announcement by Reuters was published on April 21, 2026, at 06:27 pm EDT. The article also provides a company profile for Nexgel, Inc., detailing its focus on hydrogel products for various applications and its financial outlook with analyst consensus.

Celularity Inc. (Nasdaq: CELU) has announced the closing of financing transactions with Philip A. Barach, securing $10.00 million in gross proceeds with potential for an additional $2.0 million. This financing, comprising a senior secured term loan and secured convertible notes, aims to bolster Celularity's financial position and support its focus on leveraging its placental-derived platform for healthy aging and performance optimization. The company plans to articulate its refined corporate strategy in the new year, aligning scientific capabilities with long-term opportunities in longevity and age-related diseases.

Celularity Inc. announced the closing of financing transactions with Philip A. Barach, securing $10.00 million in gross proceeds with a potential for an additional $2.0 million. This financing, consisting of a senior secured term loan and convertible notes, aims to strengthen Celularity's financial position and support its focus on leveraging its placental-derived platform for healthy aging and performance optimization. The company plans to articulate its corporate strategy more fully in the new year to align scientific capabilities with long-term opportunities in longevity and age-related diseases.

Celularity Inc. announced the closing of financing transactions that generated $10 million in gross proceeds, with potential for an additional $2 million. This funding package includes a $7 million senior secured term loan and up to $5 million in secured convertible notes, alongside warrants for 3,707,657 shares. The biotech company, focused on regenerative medicine and age-related diseases, plans to use the proceeds to support ongoing operations, strategic initiatives, and its longevity-focused platform derived from placental cells.

Celularity Inc. has secured binding financing agreements for up to $12 million from Philip A. Barach, co-founder of DoubleLine Capital LP, amidst financial challenges and a significant debt burden. This capital, including a senior secured term loan and convertible notes, is aimed at advancing the company's core placental-derived technologies focused on longevity. The financing is expected to provide flexibility for Celularity to refine its mission and focus on its therapeutic solutions.